Creating new antiviral drugs: Katherine Seley-Radtke’s innovative “fleximer” research to receive $3.5M from NIH
“Many people in the antiviral field had been pushing for many years, warning people that this kind of viral pandemic could happen,” says Katherine Seley-Radtke. Thankfully, her decades of work put her in a strong position to contribute to a new surge of antiviral research.